Renalytix and Tempus Collaborate to Enhance Kidney Risk Assessment for Diabetic Patients Renalytix has partnered with Tempus AI to expand access to kidneyintelX.dkd testing in the US, aiding diabetic kidney disease risk assessment and management.

Renalytix and Tempus Collaborate to Enhance Kidney Risk Assessment for Diabetic Patients #United_States #New_York #kidney_disease #Tempus_AI #Renalytix

Renalytix shares surge 45% on Tempus collaboration Renalytix PLC (AIM:RENX) saw its shares leap 45% in early London trading after the diagnostics group struck a deal with US health technology company Tempus...

#RENX 🚀+83%🚀 10.75p✅

MT @proactive_x
$RENX #Renalytix shares surges on Tempus #Ai collaboration tinyurl.com/2dnzjtqn

MVP Health Care and Renalytix Unite for Kidney Disease Testing to Transform Patient Care MVP Health Care and Renalytix are collaborating to enhance kidney disease testing services, improving health outcomes for those with chronic conditions.

MVP Health Care and Renalytix Unite for Kidney Disease Testing to Transform Patient Care #USA #New_York #kidney_disease #MVP_Health_Care #Renalytix